Terephthalamide-containing ligands: fast removal of iron from transferrin
- PMID: 17990009
- DOI: 10.1007/s00775-007-0314-y
Terephthalamide-containing ligands: fast removal of iron from transferrin
Abstract
The mechanism and effectiveness of iron removal from transferrin by three series of new potential therapeutic iron sequestering agents have been analyzed with regard to the structures of the chelators. All compounds are hexadentate ligands composed of a systematically varied combination of methyl-3,2-hydroxypyridinone (Me-3,2-HOPO) and 2,3-dihydroxyterephthalamide (TAM) binding units linked to a polyamine scaffold through amide linkers; each series is based on a specific backbone: tris(2-aminoethyl)amine, spermidine, or 5-LIO(TAM), where 5-LIO is 2-(2-aminoethoxy)ethylamine. Rates of iron removal from transferrin were determined spectrophotometrically for the ten ligands, which all efficiently acquire ferric ion from diferric transferrin with a hyperbolic dependence on ligand concentration (saturation kinetics). The effect of the two iron-binding subunits Me-3,2-HOPO and TAM and of the scaffold structures on iron removal ability is discussed. At the low concentrations corresponding to therapeutic dose, TAM-containing ligands exhibit the fastest rates of iron removal, which correlates with their high affinity for ferric ion and suggests the insertion of such binding units into future therapeutic chelating agents. In addition, urea polyacrylamide gel electrophoresis was used to measure the individual microscopic rates of iron removal from the three iron-bound transferrin species (diferric transferrin, N-terminal monoferric transferrin, C-terminal monoferric transferrin) by the representative chelators 5-LIO(Me-3,2-HOPO)(2)(TAM) and 5-LIO(TAMmeg)(2)(TAM), where TAMmeg is 2,3-dihydroxy-1-(methoxyethylcarbamoyl)terephthalamide. Both ligands show preferential removal from the C-terminal site of the iron-binding protein. However, cooperative effects between the two binding sites differ with the chelator. Replacement of hydroxypyridinone moieties by terephthalamide groups renders the N-terminal site more accessible to the ligand and may represent an advantage for iron chelation therapy.
Similar articles
-
Fast biological iron chelators: kinetics of iron removal from human diferric transferrin by multidentate hydroxypyridonates.J Biol Inorg Chem. 2000 Oct;5(5):634-41. doi: 10.1007/s007750000149. J Biol Inorg Chem. 2000. PMID: 11085654
-
Synthesis and thermodynamic evaluation of mixed hexadentate linear iron chelators containing hydroxypyridinone and terephthalamide units.Inorg Chem. 2006 May 1;45(9):3622-31. doi: 10.1021/ic052111a. Inorg Chem. 2006. PMID: 16634594 Free PMC article.
-
Amonabactin-mediated iron acquisition from transferrin and lactoferrin by Aeromonas hydrophila: direct measurement of individual microscopic rate constants.J Biol Inorg Chem. 2000 Feb;5(1):57-66. doi: 10.1007/pl00010655. J Biol Inorg Chem. 2000. PMID: 10766437
-
Iron mobilization from transferrin by therapeutic iron chelating agents.Biochim Biophys Acta. 2012 Mar;1820(3):282-90. doi: 10.1016/j.bbagen.2011.11.007. Epub 2011 Nov 22. Biochim Biophys Acta. 2012. PMID: 22155077 Review.
-
Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.Hemoglobin. 2006;30(2):183-200. doi: 10.1080/03630260600642450. Hemoglobin. 2006. PMID: 16798643 Review.
Cited by
-
Synthetic approaches to mixed ligand chelators on t-butylphenol-formaldehyde oligomer (PFO) platforms.Tetrahedron. 2012 Dec 2;68(48):10030-10039. doi: 10.1016/j.tet.2012.09.032. Tetrahedron. 2012. PMID: 23226883 Free PMC article.
-
Perturbation-response scanning reveals ligand entry-exit mechanisms of ferric binding protein.PLoS Comput Biol. 2009 Oct;5(10):e1000544. doi: 10.1371/journal.pcbi.1000544. Epub 2009 Oct 23. PLoS Comput Biol. 2009. PMID: 19851447 Free PMC article.
-
Deciphering the Iron Side of Stroke: Neurodegeneration at the Crossroads Between Iron Dyshomeostasis, Excitotoxicity, and Ferroptosis.Front Neurosci. 2019 Feb 19;13:85. doi: 10.3389/fnins.2019.00085. eCollection 2019. Front Neurosci. 2019. PMID: 30837827 Free PMC article. Review.
-
Di-macrocyclic terephthalamide ligands as chelators for the PET radionuclide zirconium-89.Chem Commun (Camb). 2015 Feb 11;51(12):2301-3. doi: 10.1039/c4cc09256b. Chem Commun (Camb). 2015. PMID: 25556851 Free PMC article.
-
Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial.Antioxidants (Basel). 2021 Aug 10;10(8):1270. doi: 10.3390/antiox10081270. Antioxidants (Basel). 2021. PMID: 34439518 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous